

Co-Diagnostics filed for Indian clearance for its rapid TB test following successful trials, targeting commercial sales before the year-end.
You can purchase shares of Co-Diagnostics (NASDAQ:CODX) through any online brokerage.
Other companies in Co-Diagnostics’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
Co-Diagnostics has a consensus price target of $90.00.
The stock price for Co-Diagnostics (NASDAQ: CODX) is $0.302 last updated November 9, 2026 at 5:01 PM EST.
There are no upcoming dividends for Co-Diagnostics.
Co-Diagnostics does not have any upcoming earnings scheduled.
There is no upcoming split for Co-Diagnostics.
Co-Diagnostics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA),...